Bone and mineral metabolism in patients with primary aldosteronism: A systematic review and meta-analysis
A Wang, Y Wang, H Liu, X Hu, J Li, H Xu… - Frontiers in …, 2022 - frontiersin.org
Purpose Patients with primary aldosteronism (PA) tend to exhibit a high prevalence of
osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to …
osteoporosis (OP) that may vary by whether PA is unilateral or bilateral, and responsive to …
Cross-disciplinary approach of adrenal tumors: insights into primary aldosteronism-related mineral metabolism status and osteoporotic fracture risk
Our objective was to overview the novel aspects in the field of adrenal gland neoplasms,
namely, the management of bone status with respect to primary aldosteronism (PA). In the …
namely, the management of bone status with respect to primary aldosteronism (PA). In the …
Primary aldosteronism as a cause of secondary osteoporosis
AS Salcuni, V Carnevale, C Battista… - European Journal of …, 2017 - academic.oup.com
Objective Patients with primary aldosteronism (PA) have a high prevalence of osteoporosis
(OP) and fractures (Fx). We evaluated the presence of PA in patients admitted to our …
(OP) and fractures (Fx). We evaluated the presence of PA in patients admitted to our …
The interplay between bone and heart health as reflected in medication effects: A narrative review
S Trost, N Tesfaye, T Harindhanavudhi - Women's Health, 2023 - journals.sagepub.com
There is mounting evidence of an association between osteoporosis and cardiovascular
disease that extends beyond shared risk factors for these conditions. In turn, the medications …
disease that extends beyond shared risk factors for these conditions. In turn, the medications …
Spironolactone reduces biochemical markers of bone turnover in postmenopausal women with primary aldosteronism
Context Primary aldosteronism (PA) is the most frequent form of endocrine hypertension.
Besides its deleterious impact on cardiovascular target organ damage, PA is considered to …
Besides its deleterious impact on cardiovascular target organ damage, PA is considered to …
The effect of vitamin D treatment on clinical and biochemical outcomes of primary aldosteronism
NA Ismail, NA Kamaruddin, S Azhar Shah… - Clinical …, 2020 - Wiley Online Library
Introduction Primary aldosteronism (PA) contributed to the cardiovascular disease and
metabolic alterations independent of the blood pressure level. Evidence exists that …
metabolic alterations independent of the blood pressure level. Evidence exists that …
Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea—what do we know so far?
Primary aldosteronism (PA), the most common cause of secondary hypertension, is a well-
recognized condition that can lead to cardiovascular and renal complications. PA is …
recognized condition that can lead to cardiovascular and renal complications. PA is …
The entity of connshing syndrome: Primary aldosteronism with autonomous cortisol secretion
M Carsote - Diagnostics, 2022 - mdpi.com
Connshing syndrome (CoSh)(adrenal-related synchronous aldosterone (A) and cortisol (C)
excess) represents a distinct entity among PA (primary hyperaldosteronisms) named by W …
excess) represents a distinct entity among PA (primary hyperaldosteronisms) named by W …
Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives
Adrenal incidentalomas constitute a common clinical problem with an overall prevalence of
around 2–3%, but are more common with advancing age being present in 10% of those …
around 2–3%, but are more common with advancing age being present in 10% of those …
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism–the randomized, placebo-controlled EPATH trial
N Verheyen, MR Grübler, A Meinitzer, C Trummer… - Bone, 2017 - Elsevier
Mineralocorticoid receptor (MR) antagonism may affect bone turnover via direct and indirect
pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a …
pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a …